/

Society

Ki

Not verified

Kinaset Therapeutics

What we write about

BiotechnologyEventiFood hygieneHealthPharmaceuticals

1 Press releases

View all press releases

04/09/2024

Biotechnology

Food hygiene

Health

Pharmaceuticals

Medicine - various

Eventi

Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Presentations and Poster at ERS Congress

Source

Kinaset Therapeutics

Issuer

1.00

0

Followers

0

Compatibility

0